Cost-effectiveness analysis of an additional birth dose of Hepatitis B vaccine to prevent perinatal transmission in a medical setting in Mozambique

Vaccine

Volumn 31, Issue 1, 2012, Pages 252-259

  Klingler, Corinna ^a   Thoumi, Andrea I ^a,b   Mrithinjayam, Vinod S ^a  

^a LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Additional birth dose; Hepatitis B; Mozambique; Perinatal transmission; Vaccine Cost effectiveness analysis

Indexed keywords

HEPATITIS B VACCINE;

ARTICLE; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISABILITY; DISABILITY ADJUSTED LIFE YEARS; DRUG COST; HEPATITIS B; HUMAN; MOZAMBIQUE; PERINATAL TRANSMISSION; PRIORITY JOURNAL; PROBABILITY; SENSITIVITY ANALYSIS; TREATMENT DURATION; VACCINATION; VERTICAL TRANSMISSION;

COST-BENEFIT ANALYSIS; HEPATITIS B; HEPATITIS B VACCINES; HUMANS; MOZAMBIQUE;

EID: 84870510920     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.08.007     Document Type: Article

References (60)

1. World Health Organization (WHO) Hepatitis B vaccines-WHO position paper. Wkly Epidemiol Rec 2009, 84(40):405-419.
2. Goldstein S.T., Zhou F., Hadler S.C., Bell B.P., Mast E.E., Margolis H.S. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 2005, 34(6):1329-1339.
3. GAVI Alliance GAVI Alliance Progress Report 2010 2010, Available from: http://www.gavialliance.org/resources/2009_GAVI_Alliance_Progress_Report.pdf [cited 1.5.12].
4. Griffiths U.K., Hutton G., Das Dores Pascoal E. The cost-effectiveness of introducing hepatitis B vaccine into infant immunization services in Mozambique. Health Policy Plan 2005, 20(1):50-59.
5. Ministry of Health (Republic of Mozambique) National Immunization Program-Comprehensive Multi-Year Plan (cMYP) 2012-2016 2011, Available from: http://www.google.de/url?sa=t&rct=j&q=expanded%20programm%20on%20immunization%20comprehensive%20multi-year%20mozambique&source=web&cd=4&ved=0CEEQFjAD&url=ftp%3A%2F%2Fiff-immunisation.org%2FJuly%25202011%2FMozambique%2Fcomprehensive%2520Multi%2520Year%2520Plan%2520-%2520cMYP%2520-%25201%2520-%2520EN.doc&ei=f-6fT6WVFqf-4QSlo93FAw&usg=AFQjCNGCeUX8KHMw0jL8btGLZfFRSs86_g&cad=rja [cited 1.5.12].
6. Kramvis A., Clements C.J. Implementing a birth dose of hepatitis B vaccine for home deliveries in Africa-too soon?. Vaccine 2010, 28(39):6408-6410.
7. Ministry of Health (Republic of Mozambique) Introduction of DTP-Hepatitis B Vaccine 2001, Available from: http://www.path.org/vaccineresources/files/Mozambique_DTP-HepB.pdf [cited 1.5.12].
8. Kiire C.F. The epidemiology and prophylaxis of hepatitis B in sub-Saharan Africa: a view from tropical and subtropical Africa. Gut 1996, 38(Suppl. 2):S5-S12.
9. Baker L. The face of South Africa's Expanded Programme on Immunisation (EPI) schedule. SAPJ 2010, 77(1):18-20.
10. Martinson F.E., Weigle K.A., Royce R.A., Weber D.J., Suchindran C.M., Lemon S.M. Risk factors for horizontal transmission of hepatitis B virus in a rural district in Ghana. Am J Epidemiol 1998, 147(5):478-487.
11. Vardas E., Mathai M., Blaauw D., McAnerney J., Coppin A., Sim J. Preimmunization epidemiology of hepatitis B virus infection in South African children. J Med Virol 1999, 58(2):111-115.
12. Chauvin P., Ekra D., Plotkin S.A. The cost of not implementing routine neonates immunization programmes in HBsAg high prevalence countries. Vaccine 2002, 20(23-24):2848-2850.
13. Rustgi V., Carriero D., Bachtold M., Zeldin G. Update on chronic hepatitis B. J Nurse Pract 2010, 6(8):631-639.
14. Wasmuth J.C. Hepatitis B-epidemiology, transmission and natural history. Hepatology-a clinical textbook 2010, 7-17. Flying Publishers. 2nd ed.
15. Ekra D., Herbinger K.H., Konate S., Leblond A., Fretz C., Cilote V., et al. A non-randomized vaccine effectiveness trial of accelerated infant hepatitis B immunization schedules with a first dose at birth or age 6 weeks in Cote d'Ivoire. Vaccine 2008, 26(22):2753-2761.
16. Marion S.A., Tomm Pastore M., Pi D.W., Mathias R.G. Long-term follow-up of hepatitis B vaccine in infants of carrier mothers. Am J Epidemiol 1994, 140(8):734-746.
17. Plymoth A., Viviani S., Hainaut P. Control of hepatocellular carcinoma through hepatitis B vaccination in areas of high endemicity: perspectives for global liver cancer prevention. Cancer Lett 2009, 286(1):15-21.
18. Sutanto A., Suarnawa I.M., Nelson C.M., Stewart T., Soewarso T.I. Home delivery of heat-stable vaccines in Indonesia: outreach immunization with a prefilled, single-use injection device. Bull World Health Organ 1999, 77(2):119-126.
19. World Health Organization (WHO) Preventing mother-to-child transmission of hepatitis B-operational field guidelines for delivery of the birth dose of hepatitis B vaccine 2006, World Health Organization (WHO), Geneva.
20. Instituto Nacional de Estatistica de Mocambique Multiple Indicator Cluster Survey 2008 2008, Available from: http://www.childinfo.org/files/MICSSumEng201009.pdf [cited 4.4.11].
21. Fattovich G. Natural history of hepatitis B. J Hepatol 2003, 39(Suppl. 1):S50-S58.
22. Hung H.F., Chen T.H. Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: an experience from Taiwan with high hepatitis B virus infection and Hepatitis B e Antigen positive prevalence. Vaccine 2009, 27(48):6770-6776.
23. Aggarwal R., Ghoshal U.C., Naik S.R. Assessment of cost-effectiveness of universal hepatitis B immunization in a low-income country with intermediate endemicity using a Markov model. J Hepatol 2003, 38(2):215-222.
24. Kim S.Y., Salomon J.A., Goldie S.J. Economic evaluation of hepatitis B vaccination in low-income countries: using cost-effectiveness affordability curves. Bull World Health Organ 2007, 85(11):833-842.
25. Menendez C., Sanchez-Tapias J.M., Kahigwa E., Mshinda H., Costa J., Vidal J., et al. Prevalence and mother-to-infant transmission of hepatitis viruses B, C, and E in Southern Tanzania. J Med Virol 1999, 58(3):215-220.
26. Oshitani H., Kasolo F.C., Mpabalwani M., Mizuta K., Luo N.P., Suzuki H., et al. Prevalence of hepatitis B antigens in human immunodeficiency virus type 1 seropositive and seronegative pregnant women in Zambia. Trans R Soc Trop Med Hyg 1996, 90(3):235-236.
27. Ott J.J., Stevens G.A., Groeger J., Wiersma S.T. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012, 30(12):2212-2219.
28. Beasley R.P., Trepo C., Stevens C.E., Szmuness W. The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol 1977, 105(2):94-98.
29. de Franchis R., Hadengue A., Lau G., Lavanchy D., Lok A., McIntyre N., et al. EASL international consensus conference on hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol 2003, 39(Suppl. 1):S3-S25.
30. Edmunds W.J., Medley G.F., Nokes D.J., O'Callaghan C.J., Whittle H.C., Hall A.J. Epidemiological patterns of hepatitis B virus (HBV) in highly endemic areas. Epidemiol Infect 1996, 117(2):313-325.
31. World Bank. Open Data Catalogue. Available from: [cited 4.4.11]. http://data.worldbank.org/.
32. Margolis H.S., Coleman P.J., Brown R.E., Mast E.E., Sheingold S.H., Arevalo J.A. Prevention of hepatitis B virus transmission by immunization. An economic analysis of current recommendations. JAMA 1995, 274(15):1201-1208.
33. Hyams K.C. Risks of chronicity following acute hepatitis B virus infection: a review. Clin Infect Dis 1995, 20(4):992-1000.
34. Edmunds W.J., Medley G.F., Nokes D.J., Hall A.J., Whittle H.C. The influence of age on the development of the hepatitis B carrier state. Proc Biol Sci 1993, 253(1337):197-201.
35. McMahon B.J., Helminiak C., Wainwright R.B., Bulkow L., Trimble B.A., Wainwright K. Frequency of adverse reactions to hepatitis B vaccine in 43,618 persons. Am J Med 1992, 92(3):254-256.
36. World Health Organization (WHO). Global Health Observatory Data Repository. Available from: [cited 4.4.11]. http://apps.who.int/ghodata/?vid=720.
37. Levin C.E., Nelson C.M., Widjaya A., Moniaga V., Anwar C. The costs of home delivery of a birth dose of hepatitis B vaccine in a prefilled syringe in Indonesia. Bull World Health Organ 2005, 83(6):456-461.
38. Instituto Nacional de Estatistica de Mocambique. Servicos Prestados 2004-2008. Available from: [cited 4.4.11]. http://www.ine.gov.mz/sectorias_dir/saude_dir/SER_PREST_04_08.
39. World Health Organization (WHO) Guidelines for estimating costs of introducing new vaccines into the national immunization system 2002, World Health Organization (WHO), Geneva.
40. UNICEF Supply Division. Supplies and logistics. Available from: [cited 4.4.11]. http://www.unicef.org/supply/.
41. World Health Organization (WHO). Immunization profile-South Africa. Available from: [cited 4.4.11]. http://apps.who.int/immunization_monitoring/en/globalsummary/countryprofileresult.cfm?C=zaf.
42. World Health Organization (WHO). Immunization safety. Available from: [cited 4.4.11]. http://www.who.int/immunization_safety/safe_injections/update/en/index2.html.
43. Wiersma S.T., McMahon B., Pawlotsky J.M., Thio C.L., Thursz M., Lim S.G., et al. Treatment of chronic hepatitis B virus infection in resource-constrained settings: expert panel consensus. Liver Int 2011, 31(6):755-761.
44. Tan-Torres Edejer T., Baltussen R., Adam T., Hutubessy R., Acharya A., Evans D.B., et al. Making choices in health: WHO guide to cost-effectiveness analysis 2003, World Health Organization (WHO), Geneva.
45. Sicuri E., Bardaji A., Nhampossa T., Maixenchs M., Nhacolo A., Nhalungo D., et al. Cost-effectiveness of intermittent preventive treatment of malaria in pregnancy in southern Mozambique. PLoS One 2010, 5(10):e13407.
46. World Health Organization (WHO) Global burden of disease 2004 update: disability weights for diseases and conditions 2004, Available from: http://www.who.int/healthinfo/global_burden_disease/GBD2004_DisabilityWeights.pdf [cited 4.4.11].
47. Anand S., Hanson K. Disability-adjusted life years: a critical review. J Health Econ 1997, 16(6):685-702.
48. Goodin R.E. Discounting discounting. J Publ Pol 1982, 2(01):53-71.
49. Murray C.J., Acharya A.K. Understanding DALYs (disability-adjusted life years). J Health Econ 1997, 16(6):703-730.
50. Jamison D.T., Breman J.G., Measham A.R., Alleyne G., Cleaeson M., Evans D.B., et al. Disease control priorities in developing countries 2006, The World Bank, Washington, DC. 2nd ed.
51. Fox-Rushby J.A., Hanson K. Calculating and presenting disability adjusted life years (DALYs) in cost-effectiveness analysis. Health Policy Plan 2001, 16(3):326-331.
52. World Health Organization (WHO). Mozambique: health profile. Available from: [cited 4.4.11]. http://www.who.int/gho/countries/moz.pdf.
53. World Health Organization Commission on Macroeconomics and Health Macroeconomics and health: investing in health for economic development-report of the commission on macroeconomics and health 2001, World Health Organization, Geneva.
54. Murray C.J.L., Evans D.B. Health systems performance assessment-debates methods and empiricism 2003, World Health Organization, Geneva.
55. Baltussen R., Sylla M., Mariotti S.P. Cost-effectiveness analysis of cataract surgery: a global and regional analysis. Bull World Health Organ 2004, 82(5):338-345.
56. Briggs A. Handling uncertainty in economic evaluation and presenting the results. Economic evaluation in health care: merging theory with practice 2001, 172-214. Oxford University Press, Oxford. M.F. Drummond, A. McGuire (Eds.).
57. Atherly D., Dreibelbis R., Parashar U.D., Levin C., Wecker J., Rheingans R.D. Rotavirus vaccination: cost-effectiveness and impact on child mortality in developing countries. J Infect Dis 2009, 200(Suppl. 1):S28-S38.
58. Lee C., Gong Y., Brok J., Boxall E.H., Gluud C. Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. BMJ 2006, 332(7537):328-336.
59. Lolekha S., Warachit B., Hirunyachote A., Bowonkiratikachorn P., West D.J., Poerschke G. Protective efficacy of hepatitis B vaccine without HBIG in infants of HBeAg-positive carrier mothers in Thailand. Vaccine 2002, 20(31-32):3739-3743.
60. World Health Organization (WHO) The world health report 2006: working together for health 2006, World Health Organization (WHO), Geneva.